This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Select Medical Rises 50.2% YTD: Take Profits or Bet on More Gains?
by Zacks Equity Research
SEM's profitability is being impacted by rising costs and expenses.
Select Medical Agrees to Acquire Valir Rehabilitation Hospital
by Zacks Equity Research
SEM enters a definitive agreement to acquire Valir Rehabilitation Hospital and expand its inpatient rehabilitation footprint in Oklahoma City.
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 1.69% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Q2 Boost for Tenet (THC): A Healthy Dose of Long-Term Gains
by Kaibalya Pravo Dey
Tenet (THC) shares jump 8.3% since Q2 earnings beat, as investors grow increasingly confident about the company's future prospects.
Is Select Medical (SEM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) Expands Rehabilitation Services in Central PA
by Zacks Equity Research
Select Medical (SEM) and UPMC unveil a 20-bed satellite facility of Helen M. Simpson Rehabilitation Hospital in West Shore, thus enhancing specialized inpatient rehabilitation care in Central Pennsylvania.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Select Medical (SEM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?
by Zacks Equity Research
Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Select Medical (SEM) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical's (SEM) Shares Up 12.9% Since Q1 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) revises its adjusted EBITDA guidance upward between $845 million and $885 million for 2024, the mid-point is higher than $807.4 million in 2023.
Is Select Medical (SEM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.
Select Medical (SEM) Q4 Earnings Beat on Patient Admissions
by Zacks Equity Research
Select Medical's (SEM) Q4 results reflect strong segmental contribution, aided by higher patient days and visits. Management expects 2024 adjusted EBITDA to be $830-$880 million, up from the 2023 reported figure of $807.4 million.
Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?